Michael Gelband’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Michael Gelband’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,407	Closed	-$46K	–	2754
2021 Q3	$46K	Sell	21,407 -17,600	-45%	-$38.3K	﹤0.01%	1979
2021 Q2	$106K	Buy	39,007 +26,111	+202%	+$64.9K	﹤0.01%	2136
2021 Q1	$34K	Sell	12,896 -18,881	-59%	-$53.4K	﹤0.01%	2049
2020 Q4	$88K	Buy	+31,777	New	+$92.5K	﹤0.01%	1843
2020 Q2	–	Sell	-18,300	Closed	-$45K	–	2113
2020 Q1	$45K	Buy	+18,300	New	+$66.1K	﹤0.01%	965
2019 Q3	–	Sell	-13,700	Closed	-$85K	–	1724
2019 Q2	$85K	Buy	13,700 +9,872	+258%	+$75.2K	﹤0.01%	1033
2019 Q1	$41K	Buy	+3,828	New	+$38.1K	﹤0.01%	646

Other funds holding SIOX

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Michael Gelband's SIOX Position: Q4 2021 in Review

Michael Gelband sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 21,407 shares — an estimated $46K sold.

Michael Gelband first reported a position in SIOX in Q1 2019 and held it in 7 quarters. The position peaked at $106K in Q2 2021. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

Michael Gelband reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Michael Gelband sold 21,407 Sio Gene Therapies Inc. Common Stock shares in Q4 2021, an estimated $46K.
Michael Gelband first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2019 and held it in 7 quarters.
Michael Gelband's Sio Gene Therapies Inc. Common Stock position peaked at $106K in Q2 2021.
48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.